{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:52:10Z","timestamp":1790779930702,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Michael J Fox Foundation"},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Greta and Johan Kocks Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.expneurol.2015.05.021","type":"journal-article","created":{"date-parts":[[2015,5,30]],"date-time":"2015-05-30T16:08:51Z","timestamp":1433002131000},"page":"335-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat"],"prefix":"10.1016","volume":"271","author":[{"given":"H.","family":"Iderberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Varney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Kleven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Koek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Depoort\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Cenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2015.05.021_bb0005","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/syn.20195","article-title":"Effects of sarizotan on the corticostriatal glutamate pathways","volume":"58","author":"Antonelli","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0010","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1017\/S1461145709991222","article-title":"F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity","volume":"13","author":"Assie","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb5000","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0014-2999(01)01029-9","article-title":"In the formalin model of tonic nociceptive pain, 8-OH-DPAT produces 5-HT1A receptor-mediated, behaviorally specific analgesia","volume":"421","author":"Bardin","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0015","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neures.2009.10.009","article-title":"Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats","volume":"66","author":"Bardin","year":"2010","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0020","first-page":"1605","article-title":"Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments","volume":"9","author":"Bargiotas","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0025","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0030","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/j.1476-5381.1991.tb12342.x","article-title":"Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia","volume":"103","author":"Bill","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0035","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0040","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.nbd.2012.10.013","article-title":"Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat","volume":"50","author":"Breger","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0045","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejphar.2006.01.027","article-title":"Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase","volume":"534","author":"Bruins Slot","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb5500","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0014-2999(03)01566-8","article-title":"Tolerance and inverse tolerance to the hyperalgesic and analgesic actions, respectively, of the novel analgesic, F 13640","volume":"466","author":"Bruins Slot","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0050","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in Parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain J. Neurol."},{"issue":"Suppl. 2","key":"10.1016\/j.expneurol.2015.05.021_bb0055","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1016\/j.parkreldis.2008.04.021","article-title":"Involvement of the serotonin system in l-DOPA-induced dyskinesias","volume":"14","author":"Carta","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0060","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research","volume":"27","author":"Celada","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0065","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0070","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0075","doi-asserted-by":"publisher","first-page":"670","DOI":"10.2174\/187152711797247885","article-title":"Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease","volume":"10","author":"Cenci","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0085","first-page":"40","article-title":"5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief","volume":"7","author":"Colpaert","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0080","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0028-3908(02)00119-3","article-title":"Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia","volume":"43","author":"Colpaert","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0090","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s002130000449","volume":"152","author":"Dekeyne","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0095","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0100","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.euroneuro.2010.04.005","article-title":"F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists","volume":"20","author":"Depoortere","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb6000","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02245588","article-title":"5-HT1A receptor agonists: recent developments and controversial issues","volume":"121","author":"De Vry","year":"1995","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0105","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","article-title":"Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats","volume":"229","author":"Dupre","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0110","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/JGP.0b013e31818af7ef","article-title":"Pain and its relationship to depression in Parkinson disease","volume":"17","author":"Ehrt","year":"2009","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0115","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of L-DOPA-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"issue":"Suppl. 3","key":"10.1016\/j.expneurol.2015.05.021_bb0120","doi-asserted-by":"publisher","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson's disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0125","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0166-4328(96)00118-0","article-title":"Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist","volume":"73","author":"Fletcher","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0130","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00213-013-3389-x","article-title":"5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function","volume":"231","author":"Garcia-Garcia","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0135","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0140","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/BF00174065","article-title":"Lithium decreases 5-HT1A and 5-HT2 receptor and alpha 2-adrenoceptor mediated function in mice","volume":"90","author":"Goodwin","year":"1986","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0145","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbr.2013.08.045","article-title":"Animal models of the serotonin syndrome: a systematic review","volume":"256","author":"Haberzettl","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0150","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0006-3223(90)90627-E","article-title":"Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites","volume":"28","author":"Hamik","year":"1990","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0155","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-l-DOPA-responsive problems dominate at 15years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0160","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuropharm.2015.01.012","article-title":"Activity of serotonin 5-HT1A receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia","volume":"93","author":"Iderberg","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0170","first-page":"133","article-title":"Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease","volume":"54","author":"Kannari","year":"2002","journal-title":"No To Shinkei Brain Nerve"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0175","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0014-2999(01)01011-1","article-title":"5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential","volume":"420","author":"Koek","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0180","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0185","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00213-011-2569-9","article-title":"In vivo electrophysiological and neurochemical effects of the selective 5-HT(1A) receptor agonist, F13640, at pre- and postsynaptic 5-HT (1A) receptors in the rat","volume":"221","author":"Llado-Pelfort","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0190","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0195","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1046\/j.1471-4159.2003.01632.x","article-title":"Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia","volume":"84","author":"Lundblad","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0200","first-page":"189","article-title":"Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life","volume":"2","author":"Manson","year":"2012","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0205","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/00001756-200505120-00009","article-title":"8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease","volume":"16","author":"Mignon","year":"2005","journal-title":"Neuroreport"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0210","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fncir.2014.00021","article-title":"Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease","volume":"8","author":"Miguelez","year":"2014","journal-title":"Front. Neural Circuits"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0215","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.expneurol.2009.05.033","article-title":"Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model","volume":"219","author":"Munoz","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0220","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/10799899209074797","article-title":"Brainstem 5-hydroxytrytamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat: myoclonus and other serotonergic behaviors","volume":"12","author":"Murthy","year":"1992","journal-title":"J. Recept. Res."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0225","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1471-4159.2011.07598.x","article-title":"Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning","volume":"120","author":"Nahimi","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0240","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/npy.11.12","article-title":"Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders","volume":"1","author":"Newman-Tancredi","year":"2011","journal-title":"Neuropsychiatry"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0230","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00210-003-0788-2","article-title":"Comparison of hippocampal G protein activation by 5-HT1A receptor agonists and the atypical antipsychotics clozapine and S16924","volume":"368","author":"Newman-Tancredi","year":"2003","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0235","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0245","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","article-title":"Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)","volume":"27","author":"Olanow","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0250","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease","volume":"28","author":"Olanow","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0255","first-page":"313","article-title":"Who dropped the ball on l-DOPA? A patient's lament","volume":"4","author":"Palfreman","year":"2014","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0260","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/mds.25218","article-title":"Levodopa infusion does not decrease the onset of abnormal involuntary movements in Parkinsonian rats","volume":"28","author":"Papathanou","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0265","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0006-2952(01)00575-5","article-title":"Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins","volume":"61","author":"Pauwels","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0270","series-title":"The rat brain in stereotaxic coordinates, Vol","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0275","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0006-3223(85)90194-5","article-title":"Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors","volume":"20","author":"Peroutka","year":"1985","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0280","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/14740338.2015.988137","article-title":"Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease","volume":"14","author":"Pilleri","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0285","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2012.02.022","article-title":"Affective symptoms and cognitive functions in Parkinson's disease","volume":"317","author":"Poletti","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0290","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0295","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0014-2999(78)90118-8","article-title":"Behavioural despair in rats: a new model sensitive to antidepressant treatments","volume":"47","author":"Porsolt","year":"1978","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0300","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00008877-200006000-00013","article-title":"Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy","volume":"11","author":"Prinssen","year":"2000","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0305","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0014-2999(02)02430-5","article-title":"5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy","volume":"453","author":"Prinssen","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0310","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.clineuro.2013.08.022","article-title":"Pain in Parkinson's disease: analysis and literature review","volume":"115","author":"Rana","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0315","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.parkreldis.2014.11.019","article-title":"Anxiety in Parkinson's disease: symptom dimensions and overlap with depression and autonomic failure","volume":"21","author":"Rutten","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0320","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of l-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0325","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in Parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0330","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145C","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0335","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0340","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/brain\/awu409","article-title":"Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study","volume":"138","author":"Svenningsson","year":"2015","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0345","first-page":"745947","article-title":"Clinical aspects and management of levodopa-induced dyskinesia","volume":"2012","author":"Tambasco","year":"2012","journal-title":"Park. Dis."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0350","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","article-title":"Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats","volume":"10","author":"Tanaka","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0355","first-page":"2547","article-title":"Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output","volume":"231","author":"van Amsterdam","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2015.05.021_bb0360","first-page":"1100","article-title":"Radiopharmacological evaluation of [18F]F13640, a novel 5-HT1A receptor agonist","volume":"55","author":"Vidal","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0365","doi-asserted-by":"publisher","first-page":"9448","DOI":"10.1523\/JNEUROSCI.0944-06.2006","article-title":"Endothelial proliferation and increased blood\u2013brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-l-alanine-induced dyskinesia","volume":"26","author":"Westin","year":"2006","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.expneurol.2015.05.021_bb0370","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448861530008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448861530008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T06:54:31Z","timestamp":1537599271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448861530008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":76,"alternative-id":["S001448861530008X"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2015.05.021","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NLX-112, a novel 5-HT1A receptor agonist for the treatment of l-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2015.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}